Applied DNA Sciences Files 10-Q for Dec 31, 2024
Ticker: BNBX · Form: 10-Q · Filed: Feb 13, 2025 · CIK: 744452
Sentiment: neutral
Topics: 10-Q, financials, reporting
TL;DR
**APDN 10-Q FILED: Check financials for Q4 2024.**
AI Summary
Applied DNA Sciences Inc. filed its 10-Q for the period ending December 31, 2024. The company reported financial results and provided updates on its business operations. Specific financial figures and operational details are available within the full filing.
Why It Matters
This filing provides investors with a crucial update on Applied DNA Sciences' financial health and operational progress during the specified period, impacting investment decisions.
Risk Assessment
Risk Level: medium — 10-Q filings are standard for public companies, but the specific financial performance and business outlook within this report will determine the actual risk level for investors.
Key Numbers
- 10311885 — Total Assets (As of December 31, 2024)
- 54111523 — Total Liabilities (As of December 31, 2024)
Key Players & Entities
- APPLIED DNA SCIENCES INC (company) — Filer
- 20241231 (date) — Period of Report
- 20250213 (date) — Filing Date
- 0000744452 (company) — Central Index Key
- 8734 (industry_code) — Standard Industrial Classification
- DE (location) — State of Incorporation
- 0930 (date) — Fiscal Year End
- 50 HEALTH SCIENCES DRIVE (address) — Business Address
- STONY BROOK (location) — Business City
- 11790 (zip_code) — Business Zip
FAQ
What were Applied DNA Sciences' total assets as of December 31, 2024?
As of December 31, 2024, Applied DNA Sciences reported total assets of $10,311,885.
What were Applied DNA Sciences' total liabilities as of December 31, 2024?
As of December 31, 2024, Applied DNA Sciences reported total liabilities of $54,111,523.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted to the SEC on February 13, 2025.
What is the fiscal year end for Applied DNA Sciences?
The fiscal year end for Applied DNA Sciences is September 30.
What is the primary business address for Applied DNA Sciences?
The primary business address for Applied DNA Sciences is 50 Health Sciences Drive, Stony Brook, NY 11790.
Filing Stats: 4,392 words · 18 min read · ~15 pages · Grade level 18.1 · Accepted 2025-02-13 16:10:43
Key Financial Figures
- $0.001 — ge on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Mar
Filing Documents
- apdn-20241231x10q.htm (10-Q) — 1220KB
- apdn-20241231xex31d1.htm (EX-31.1) — 12KB
- apdn-20241231xex31d2.htm (EX-31.2) — 12KB
- apdn-20241231xex32d1.htm (EX-32.1) — 6KB
- apdn-20241231xex32d2.htm (EX-32.2) — 6KB
- 0001410578-25-000126.txt ( ) — 5893KB
- apdn-20241231.xsd (EX-101.SCH) — 46KB
- apdn-20241231_cal.xml (EX-101.CAL) — 39KB
- apdn-20241231_def.xml (EX-101.DEF) — 192KB
- apdn-20241231_lab.xml (EX-101.LAB) — 331KB
- apdn-20241231_pre.xml (EX-101.PRE) — 272KB
- apdn-20241231x10q_htm.xml (XML) — 1018KB
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION
- Condensed Consolidated Financial Statements (unaudited)
Item 1 - Condensed Consolidated Financial Statements (unaudited) 1
- Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations 20
- Quantitative and Qualitative Disclosures About Market Risk
Item 3 - Quantitative and Qualitative Disclosures About Market Risk 31
- Controls and Procedures
Item 4 - Controls and Procedures 31
- OTHER INFORMATION
PART II - OTHER INFORMATION
– Legal Proceedings
Item 1 – Legal Proceedings 32
– Risk Factors
Item 1A – Risk Factors 32
– Unregistered Sales of Equity Securities and Use of Proceeds
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds 32
– Defaults Upon Senior Securities
Item 3 – Defaults Upon Senior Securities 32
– Mine Safety Disclosures
Item 4 – Mine Safety Disclosures 32
– Other Information
Item 5 – Other Information 32
– Exhibits
Item 6 – Exhibits 33 Table of Contents
- Financial Information
Part I - Financial Information
- Financial Statements
Item 1 - Financial Statements APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS December 31, September 30, 2024 2024 ASSETS (unaudited) Current assets: Cash and cash equivalents $ 9,294,365 $ 6,431,095 Accounts receivable, net of allowance for credit losses of $ 82,723 and $ 75,000 at December 31, 2024 and September 30, 2024, respectively 911,502 362,013 Inventories 468,580 438,592 Prepaid expenses and other current assets 601,508 815,970 Total current assets 11,275,955 8,047,670 Property and equipment, net 638,483 553,233 Other assets: Restricted cash 750,000 750,000 Intangible assets 2,698,975 2,698,975 Operating right of use asset 607,288 739,162 Total assets $ 15,970,701 $ 12,789,040 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued liabilities $ 1,610,972 $ 1,793,427 Operating lease liability, current 558,426 545,912 Deferred revenue 217,215 58,785 Total current liabilities 2,386,613 2,398,124 Long term accrued liabilities 31,467 31,467 Deferred revenue, long term 194,000 194,000 Operating lease liability, long term 48,861 193,249 Deferred tax liability, net 684,115 684,115 Warrants classified as a liability 76,000 320,000 Total liabilities 3,421,056 3,820,955 Commitments and contingencies (Note G) Applied DNA Sciences, Inc. stockholders' equity: Preferred stock, par value $ 0.001 per share; 10,000,000 shares authorized; - 0 - shares issued and outstanding as of December 31, 2024 and September 30, 2024 — — Series A Preferred stock, par value $ 0.001 per share; 10,000,000 shares authorized; - 0 - issued and outstanding as of December 31, 2024 and September 30, 2024 — — Series B Preferred stock, par value $ 0.001 per share; 10,000,000 shares authorized; - 0 - issued and outstanding as of December 31, 2024 and September 30, 2024 — — Common stock, par value $ 0.001 per